Abstract 1493P
Background
The FAMCARE-P13 is a PREM (Patient Reported Experience Measure) developed to assess the level of satisfaction about care received by advanced cancer patients. This self-compiled questionnaire consists of 13 items, scored on a 5-point Likert scale. The aim of this study was the cultural adaptation of the FAMCARE-P13 questionnaire-Italian version, as well as the evaluation of its psychometric properties in advanced cancer outpatients.
Methods
This monocentric study was conducted from January 2022 to November 2023. The tool has been adapted following the forward-back translation method. After a pre-test version on a sample of 30 patients, the tool was administered monthly, for six months, to outpatients with metastatic cancer. An exploratory descriptive and a confirmatory factor (CFA) analyses were conducted to evaluate the presence of underlying components, explained by the 13 items. The Comparative Fit Index and the Tucker-Lewis Index were used as goodness-of-fit indices. For assess the reliability of these indices, the residual root mean square value of approximation was used. The internal consistency was determined by calculating Cronbach's αcoefficient. To evaluate the reliability over time, a test-retest was administered to 30 patients; the global intra-class correlation coefficient (ICC) and the ICC for each item were calculated on these data. The significance level was set at. 05.
Results
The Italian translation was judged valid by translators and reviewers. A total of 319 patients have been enrolled: 59.5% of them declared themselves very satisfied, 37.9% were satisfied and 2.6% responded with the uncertain/very dissatisfied/dissatisfied to the different items. The CFA shows that the Italian version of the tool had a one-factor structure with CFI and TLI of. 92 and. 90 respectively, and RMSEA=. 10 (.12 -. 08). The satisfaction was closely related to the items of doctors' availability and caregiver participation. Cronbach's αwas >. 93 (.90 -. 95), showing satisfactory internal consistency. Even over time the test-retest analysis showed a stability, with a global ICC of 0.607 (p-value <0.0001).
Conclusions
The Italian version of the FAMCARE-P13 is a valid instrument to assess the level of satisfaction about care received by patients with advanced cancer.
Clinical trial identification
NCT04936568.
Editorial acknowledgement
Legal entity responsible for the study
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
Funding
Research funded by Ministero della Salute (Italy).
Disclosure
E. Zecca: Other, Invited Speaker: Amgen. A.T. Caraceni: Other, Invited Speaker: Angelini, Molteni, Pfizer, Eli Lilly, Kyowa Kirin, Shionogi. All other authors have declared no conflicts of interest.
Resources from the same session
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10
1563P - Increasing the earlier detection of lung cancer: A toolbox for change
Presenter: Helena Wilcox
Session: Poster session 10